Adaptive immunity to SARS-CoV-2 in cancer patients: The CAPTURE study
| Autor: | Nicholas van As, Bram Snijders, Scott Thomas Colville Shepherd, Steve Gamblin, Kate Young, Adrian Hayday, James Larkin, Ben Shum, Laura Amanda Boos, Phillip Hobson, Tim Slattery, Georgina H. Cornish, Ana Agua-Doce, Olivia Curtis, Joanne Droney, Mike Gavrielides, Alison Reid, Helen R. Flynn, Katalin A. Wilkinson, Anthony J. Swerdlow, James I. MacRae, Susana Banerjee, Lewis Au, Shreerang Bhide, Michael Howell, Martin Pule, Nicholas C. Turner, Robin L. Jones, Fiona Byrne, Spyridon Gennatas, Christina Messiou, Richard Stone, Liam Welsh, Yasir Khan, Zayd Tippu, Firza Gronthoud, Camilla Gomes, Ruth Harvey, Naureen Starling, Maddalena Cerrone, Sacheen Kumar, Wenyi Xie, Barry Ward, Alicia Okines, Kevin J. Harrington, George Kassiotis, Nadia Yousaf, Annika Fendler, Kevin W. Ng, Kate Tatham, Jerome Nicod, Emma Nye, Andrew Furness, Shaman Jhanji, Simon Caidan, David Cunningham, Leila Mekkaoui, Samra Turajlic, Charles Swanton, Camille L. Gerard, Robert L. Goldstone, Ian Chau, Jennifer Rusby, Emma Nicholson, Isla Leslie, Robert J. Wilkinson, Lisa Pickering, Sonia Ghandi |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
medicine.medical_specialty education.field_of_study biology business.industry Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Population Cancer Acquired immune system medicine.disease Vaccination Immune profiling Immune system Internal medicine medicine biology.protein Antibody business education |
| Popis: | SUMMARYThere is a pressing need to characterise the nature, extent and duration of immune response to SARS-CoV-2 in cancer patients and inform risk-reduction strategies and preserve cancer outcomes. CAPTURE is a prospective, longitudinal cohort study of cancer patients and healthcare workers (HCWs) integrating longitudinal immune profiling and clinical annotation. We evaluated 529 blood samples and 1051 oronasopharyngeal swabs from 144 cancer patients and 73 HCWs and correlated with >200 clinical variables. In patients with solid cancers and HCWs, S1-reactive and neutralising antibodies to SARS-CoV-2 were detectable five months post-infection. SARS-CoV-2-specific T-cell responses were detected, and CD4+T-cell responses correlated with S1 antibody levels. Patients with haematological malignancies had impaired but partially compensated immune responses. Overall, cancer stage, disease status, and therapies did not correlate with immune responses. These findings have implications for understanding individual risks and potential effectiveness of SARS-CoV-2 vaccination in the cancer population. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|